Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3008402	s-meoh	— (—)	500	651	100.00%	Distribution not available
3008402	s-meoh	mmol/l (mmol/l)	45	50	74.00%

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Substance abuse, excluding more controls

391

51.61

307.65

1.4

1.0

1.16

—

mmol/l

—

Mood disorders, excluding more controls

238

18.71

207.37

1.6

1.0

1.00

—

mmol/l

—

Anxiety disorders, excluding more controls

173

17.05

154.95

1.7

1.0

0.96

—

mmol/l

—

Convulsions, not elsewhere classified

114

14.74

126.95

1.7

1.2

—

mmol/l

—

Nonorganic sleeping disorders, excluding more controls

20.86

71.58

1.2

1.0

—

mmol/l

—

Selective serotonin reuptake inhibitors

170

165

5.36

65.21

1.7

1.1

0.94

—

mmol/l

—

Traumatic subdural haemorrhage

15.69

55.62

1.1

1.2

—

mmol/l

—

Non-selective monoamine reuptake inhibitors

7.49

46.27

1.1

—

mmol/l

—

Fracture of skull and facial bones

7.71

38.18

1.2

—

mmol/l

—

Mental and behavioural disorders due to opioids

31.49

30.43

1.2

1.5

—

Viral hepatitis, IBD co-morbidity

45.53

29.65

1.2

1.1

—

mmol/l

—

Explicit bacterial Sepsis

9.71

24.98

1.1

1.3

—

Explicit bacterial Sepsis, including avohilmo

9.71

24.98

1.1

1.3

—

Early onset COPD, excluding more controls

5.62

19.84

1.2

—

mmol/l

—

Hernia of abdominal wall, postoperative

6.64

18.92

1.3

1.1

—

Somnolence, stupor and coma

21.05

18.62

1.5

1.6

—

mmol/l

—

Other and unspecified mood [affective] disorders

15.09

14.86

1.5

1.0

—

Non-invasive ventilation

18.14

13.46

1.0

—

Atrial fibrillation and flutter with reimbursement

4.70

13.11

1.1

—

mmol/l

—

Disorders of lipoprotein metabolism and other lipidaemias

193

2.58

12.81

1.1

1.2

—

1.06

mmol/l

—

Psychotic depression

32.16

12.56

1.2

1.0

—

mmol/l

—

Traumatic subarachnoid haemorrhage

24.50

12.47

1.1

1.3

—

mmol/l

—

Pure hypercholesterolaemia

169

2.67

11.98

1.1

1.3

—

1.06

mmol/l

—

Other symptoms and signs involving general sensations and perceptions

13.47

11.94

1.2

1.5

—

Speech and linguistic disorders, excluding more controls

20.16

10.31

1.1

1.0

—

Other maltreatment syndromes

13.23

10.17

1.1

1.5

—

Other heart diseases, wide

108

321

2.04

9.96

1.1

1.4

—

0.96

mmol/l

—

Cardiac arrest

9.48

9.86

1.1

1.2

—

mmol/l

—

Necrosis of pulp, including avohilmo

364

2.17

9.69

1.2

1.4

—

1.05

mmol/l

—

Hard cardiovascular diseases

266

2.09

9.24

1.2

—

0.96

mmol/l

—

Hypertensive heart and/or renal disease

3.72

8.73

1.1

—

mmol/l

—

Dissocial personality disorder

20.35

8.49

1.5

1.0

—

mmol/l

—

Toxic effect of organic solvents

+∞

8.41

10.1

0.0

—

mmol/l

—

Alcohol abuse counselling and surveillance

17.44

8.10

1.9

1.0

—

Periapical abscess

284

2.19

7.72

1.2

—

0.93

mmol/l

—

Injury of other and unspecified intrathoracic organs

6.37

7.70

1.4

1.3

—

mmol/l

—

Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

291

2.16

7.70

1.1

1.2

—

1.16

mmol/l

—

Other diseases of pleura

180

2.42

7.63

1.1

1.3

—

1.00

mmol/l

—

Hypertensive Heart Disease

3.65

7.46

1.1

1.2

—

Implicit fungal Sepsis, including avohilmo

7.65

7.38

1.1

1.3

—

Dissociative [conversion] disorders

12.07

7.08

6.9

1.6

—

Major coronary heart disease event excluding revascularizations

221

2.06

6.86

1.2

—

1.30

mmol/l

—

Focal brain injury

8.27

6.82

1.0

1.2

—

mmol/l

—

Symptoms and signs involving emotional state

11.00

6.80

1.4

1.7

—

Conduct disorder

16.83

6.75

7.2

1.0

—

Respiratory diseases principally affecting the interstitium, IBD co-morbidites

8.09

6.68

1.1

—

mmol/l

—

Monoamine oxidase A inhibitors

6.42

6.62

1.1

1.0

—

mmol/l

—

Alcoholic gastritis

18.26

6.28

2.3

1.4

—

mmol/l

—

Toxic effect of corrosive substances

+∞

6.28

1.2

0.0

—

mmol/l

—

Personal history of certain other diseases

18.17

6.27

1.1

1.0

—

Folate deficiency anaemia

+∞

6.26

1.0

0.0

—

mmol/l

—

Agoraphobia

12.57

6.08

1.0

1.6

—

Open wound of abdomen, lower back and pelvis

8.64

6.06

1.3

1.2

—

mmol/l

—

Hepatic failure, not elsewhere classified

6.72

6.04

1.0

1.4

—

mmol/l

—

Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence

6.56

5.93

1.1

1.8

—

Fall on same level involving ice and snow

327

1.93

5.71

1.4

—

0.93

mmol/l

—

Ascites

6.11

5.68

1.3

1.2

—

mmol/l

—

Osteopathies and chondropathies

267

1.99

5.65

1.1

1.5

—

0.96

mmol/l

—

Neuromuscular dysfunction of bladder

4.74

5.60

4.6

1.1

—

mmol/l

—

Hernia of abdominal wall

248

2.06

5.57

1.2

—

0.96

mmol/l

—

Implicit fungal Sepsis

8.38

5.06

1.1

1.6

—

Diffuse brain injury

10.05

5.02

1.1

1.2

—

mmol/l

—

Other and unspecified intracranial injuries

11.49

4.79

1.3

1.7

—

mmol/l

—

Fungal Sepsis

7.18

4.65

1.1

1.5

—

Symptoms and signs concerning food and fluid intake

5.00

4.61

1.0

1.3

—

Toxic liver disease

14.14

4.58

1.1

1.0

—

14.10

4.58

1.1

1.2

—

Cirrhosis of liver, NAS

5.24

4.45

1.0

1.1

—

mmol/l

—

Any dementia, excluding more controls

3.17

4.34

1.2

1.1

—

mmol/l

—

Respiratory insufficiency

5.88

4.11

1.1

1.4

—

mmol/l

—

Acute gastritis

4.15

3.70

1.0

1.3

—

Mental retardation, excluding more controls

11.61

3.68

1.7

1.0

—

Malignant neoplasm of oral cavity

6.69

3.67

1.0

1.2

—

Unspecified jaundice

6.69

3.67

1.0

1.4

—

mmol/l

—

Special screening examination for infectious and parasitic diseases

2.40

3.63

1.1

1.2

—

Coxibs

2.43

3.56

1.1

1.3

—

Hypothyroidism, drug reimbursement

6.98

3.51

1.0

—

Barrett oesophagus

5.31

3.51

1.8

1.1

—

mmol/l

—

Malignant neoplasm of oral cavity, including Hilmo

5.31

3.51

1.0

1.1

—

Other diseases of pancreas

3.62

3.49

1.2

—

mmol/l

—

Thiazolidinediones

3.62

3.49

1.0

1.2

—

Fibrosis and cirrhosis of liver

3.88

3.48

1.0

1.2

—

mmol/l

—

Pneumonia due to Streptococcus pneumoniae

4.75

3.24

1.0

1.5

—

Intestinal adhesions without obstruction

3.56

2.99

1.1

1.4

—

Myocarditis

4.72

2.91

1.1

—

ILD, hospital admission 2, with pulmonary infections

3.44

2.89

1.1

1.2

—

Intestinal malabsorption

4.11

2.88

1.6

1.3

—

mmol/l

—

Oesophagitis

4.10

2.88

1.8

1.1

—

mmol/l

—

Other diseases of anus and rectum

128

2.02

2.87

1.1

1.2

—

mmol/l

—

Generalized epilepsy, strict definition

6.70

2.87

2.0

1.2

—

Carrier of infectious disease

6.70

2.87

1.3

1.7

—

Paralytic ileus

5.40

2.87

1.1

1.5

—

Other blood glucose lowering drugs, excl. Insulins

2.64

2.79

1.1

1.3

—

mmol/l

—

Unknown and unspecified causes of morbidity

3.92

2.77

2.0

1.3

—

Malignant neoplasm of testis

8.38

2.75

1.0

1.3

—

mmol/l

—

Allergic purpura

5.02

2.73

2.7

1.5

—

Neuralgia and neuritis, unspecified

3.76

2.67

1.3

—

Vitamin B12 deficiency anaemia

3.15

2.64

1.2

—

Special screening examination for other diseases and disorders

2.93

2.61

1.1

1.2

—

Malignant neoplasm of testis, including Hilmo

7.18

2.55

1.0

1.3

—

mmol/l

—

Other diseases of intestine

2.36

2.55

1.4

1.3

—

Diseases of arteries, arterioles and capillaries

257

1.57

2.53

1.1

1.2

—

1.03

mmol/l

—

Vascular disorders of the intestines

3.81

2.46

1.1

1.3

—

Prurigo nodularis

6.28

2.37

1.0

1.6

—

mmol/l

—

Moderate visual impairment, binocular

6.27

2.37

1.4

1.1

—

mmol/l

—

Mumps

4.64

2.27

1.0

1.4

—

Mumps, including avohilmo

4.64

2.27

1.0

1.4

—

Burns and corrosions confined to eye and internal organs

4.63

2.27

1.3

1.4

—

Autoimmune hepatitis, wide definition

3.49

2.27

1.3

—

mmol/l

—

Malignant neoplasm of head and neck

2.86

2.20

1.0

1.1

—

mmol/l

—

Injury of eye and orbit

2.50

2.18

1.2

—

Schizotypal disorder

5.02

2.07

1.0

1.5

—

Residual foreign body in soft tissue

3.08

2.01

1.3

—

Malignant neoplasm of head and neck, including Hilmo

2.50

2.01

1.0

1.2

—

mmol/l

—

Injury of nerves at wrist and hand level

3.76

1.93

1.0

1.1

—

mmol/l

—

Olecranon bursitis

2.97

1.93

1.1

1.6

—

Other inflammatory liver diseases

2.97

1.93

1.3

—

mmol/l

—

Oxicams

2.10

1.90

1.1

1.0

—

mmol/l

—

Other diseases of stomach and duodenum

2.86

1.86

1.8

1.3

—

Complications of other internal prosthetic devices, implants and grafts

3.54

1.84

1.2

1.4

—

mmol/l

—

Volvulus

4.18

1.82

1.0

1.7

—

mmol/l

—

Haemorrhage, not elsewhere classified

4.18

1.82

1.0

1.7

—

mmol/l

—

Major coronary heart disease event

301

1.39

1.81

1.2

—

1.04

mmol/l

—

Trigger finger

2.22

1.73

1.1

1.4

—

mmol/l

—

Other arrhythmias

242

1.45

1.61

1.1

1.5

—

0.93

mmol/l

—

Alzheimer disease, excluding more controls

3.24

1.60

1.5

1.0

—

Lichen simplex chronicus and prurigo

2.50

1.59

1.0

1.2

—

mmol/l

—

Abnormal blood-pressure reading, without diagnosis

3.01

1.58

1.0

1.3

—

Osteoporosis with pathological fracture (FG)

3.00

1.58

1.0

1.3

—

mmol/l

—

Congenital malformations, deformations and chromosomal abnormalities

343

1.41

1.57

1.1

1.4

—

0.92

mmol/l

—

Infective dermatitis

2.20

1.56

1.3

1.2

—

mmol/l

—

Other diseases of oesophagus

2.43

1.53

1.1

1.2

—

mmol/l

—

Faecal incontinence

2.60

1.51

1.0

1.2

—

Pruritus

2.22

1.46

1.3

1.2

—

Secondary uncertain malignant neoplasm

2.22

1.46

1.4

1.1

—

mmol/l

—

Enlarged lymph nodes

2.22

1.46

1.4

1.2

—

mmol/l

—

Plantar fascial fibromatosis

2.31

1.43

1.2

—

mmol/l

—

Malignant neoplasm of eye, brain and central nervous system, including Hilmo

2.42

1.39

1.1

—

mmol/l

—

Chronic hepatitis, not elsewhere classified

2.95

1.36

1.0

1.4

—

Injury of muscle and tendon at wrist and hand level

1.91

1.33

1.0

1.2

—

Other retinal disorders

259

1.38

1.28

1.0

1.3

—

1.00

mmol/l

—

Seborrhoeic dermatitis

2.00

1.23

1.3

1.2

—

mmol/l

—

Congenital malformations, deformations and chromosomal abnormalities, including avohilmo

371

1.33

1.20

1.1

1.4

—

0.96

mmol/l

—

Adrenocortical insufficiency

2.50

1.15

1.0

1.3

—

mmol/l

—

Secondary and unspecified malignant neoplasm of lymph nodes

2.34

1.12

1.6

1.1

—

mmol/l

—

Benign neoplasm: Colon

250

1.39

1.12

1.2

—

1.00

mmol/l

—

Malignant neoplasm of brain, including Hilmo

2.38

1.09

1.2

1.1

—

mmol/l

—

Other bursopathies

1.92

1.06

1.2

1.3

—

mmol/l

—

Unspecified urinary incontinence

2.00

1.00

1.0

1.2

—

Oral corticosteroids

413

1.22

0.98

1.8

1.2

—

1.05

mmol/l

—

Irritable bowel syndrome

108

1.57

0.96

1.2

—

mmol/l

—

Excessive attrition of teeth

380

1.28

0.90

1.2

1.4

—

0.96

mmol/l

—

Malignant neoplasm of bladder, including Hilmo

1.93

0.89

1.0

1.1

—

mmol/l

—

Percutaneous Coronary Intervention

276

1.26

0.86

1.2

—

1.02

mmol/l

—

Adhesive capsulitis of shoulder

1.72

0.86

1.2

1.3

—

Benign neoplasm of colon, rectum, anus and anal canal

289

1.29

0.85

1.2

—

1.03

mmol/l

—

Synovial cyst of popliteal space [Baker]

1.88

0.81

1.0

1.3

—

mmol/l

—

Inflammatory disease of cervix uteri

0.00

0.79

0.0

1.3

—

Other contact dermatitis

1.77

0.76

1.2

—

mmol/l

—

Excessive earwax

336

0.75

1.4

—

1.03

mmol/l

—

Nummular dermatitis

1.80

0.72

1.0

1.2

—

mmol/l

—

Chronic laryngitis and laryngotracheitis

1.61

0.72

1.1

—

Other symptoms and signs involving the circulatory and respiratory systems

1.92

0.70

2.4

1.2

—

Female infertility, cervical, vaginal, other or unspecified origin

0.57

0.69

1.0

1.1

—

mmol/l

—

Disorders of choroid and retina

342

1.21

0.68

1.0

1.2

—

1.13

mmol/l

—

Female infertility

0.60

0.66

1.0

—

mmol/l

—

Coronary revascularization (ANGIO or CABG)

276

1.21

0.65

1.2

—

1.02

mmol/l

—

Other inflammation of eyelid, including avohilmo

270

0.74

0.64

1.1

1.5

—

0.88

—

Inflammatory bowel disease treatment related agents

427

1.16

0.62

1.7

1.2

—

1.05

mmol/l

—

Spinal stenosis

192

1.27

0.60

1.1

1.2

—

1.34

mmol/l

—

Other menopausal disorders

0.60

1.1

—

mmol/l

—

Malignant neoplasm of ovary, including Hilmo

0.00

0.60

0.0

1.1

—

Metatarsalgia

1.54

0.53

1.0

1.2

—

Cholecystitis

1.46

0.46

1.0

1.1

—

mmol/l

—

Artificial joint operation, meniscal resection

382

0.87

0.42

1.1

1.2

—

1.09

mmol/l

—

Other articular cartilage disorders

0.00

0.41

0.0

1.5

—

Systemic lupus erythematosus, unspecified

0.00

0.41

0.0

1.4

—

SLE, strict definition

0.00

0.41

0.0

1.4

—

SLE, ICD10

0.00

0.41

0.0

1.4

—

Systemic lupus erythematosus

0.00

0.41

0.0

1.4

—

Malignant neoplasm of mesothelium and soft tissue

0.00

0.41

0.0

1.2

—

Malignant neoplasm of ovary

0.00

0.41

0.0

1.1

—

Other benign neoplasms of uterus

0.00

0.41

0.0

1.4

—

Disorders of thyroid, IBD co-morbidities

1.49

0.41

1.2

1.6

—

Disorders of tooth development and eruption

1.43

0.40

1.1

—

mmol/l

—

Other noninflammatory disorders of vulva and perineum

1.47

0.40

1.4

1.0

—

mmol/l

—

Female infertility, tubal origin

0.00

0.40

0.0

1.1

—

Temporomandibular joint disorders, including avohilmo

230

0.80

0.39

1.3

1.5

—

0.88

mmol/l

—

Twin gestation

1.43

0.39

2.0

1.1

—

Medial epicondylitis

0.00

0.39

0.0

1.4

—

Other noninflammatory disorders of cervix uteri

0.00

0.39

0.0

1.1

—

Oter anti-inflammatory and antirheumatic agents, non-steroids

1.30

0.37

1.1

1.0

—

Malignant neoplasm of urinary organs

1.35

0.37

1.0

1.1

—

Polyp of the female genital tract

0.73

0.36

1.0

1.1

—

Fenamates

1.46

0.36

1.8

1.0

—

Emergency coronary revascularization (for ACS)

316

1.13

0.35

1.2

—

1.04

mmol/l

—

Other enthesopathy of foot (+metatarsalgia)

1.40

0.35

1.0

1.2

—

Uterine polyps

0.75

0.28

1.0

1.1

—

Lateral epicondylitis

1.25

0.27

1.1

1.3

—

Malignant neoplasm of bronchus and lung

1.22

0.27

1.4

1.2

—

mmol/l

—

Gonarthrosis,primary

333

0.90

0.25

1.2

—

1.24

mmol/l

—

Other noninflammatory disorders of uterus, except cervix

0.71

0.24

1.0

1.1

—

mmol/l

—

Multiple gestation

1.32

0.23

2.0

1.1

—

Disorders of eyelid, lacrimal system and orbit

378

0.91

0.23

1.0

1.4

—

1.00

mmol/l

—

Malignant neoplasm of urinary organs, including Hilmo

1.19

0.21

1.0

1.1

—

Other disorders of breast and lactation associated with childbirth

0.00

0.21

0.0

1.1

—

Other specified/unspecified deforming dorsopathies

0.00

0.21

0.0

1.5

—

Venous complications and haemorrhoids in pregnancy

0.00

0.21

0.0

1.5

—

Complications associated with artificial fertilization

0.00

0.21

0.0

1.0

—

Primary biliary cholangitis (PBC)

0.00

0.21

0.0

1.5

—

Habitual aborter

0.00

0.21

0.0

1.0

—

Graves ophthalmopathy

0.00

0.21

0.0

1.5

—

Other and unspecified nail disorders

0.00

0.21

0.0

1.6

—

Granulomatous disorders of skin and subcutaneous tissue

0.00

0.21

0.0

1.0

—

Rare circulating lymphoid malignancy, including Hilmo

0.00

0.21

0.0

1.3

—

Pneumonia due to other infectious organisms, not elsewhere classified

0.00

0.21

0.0

1.7

—

Adenocarcinoma and ductal carcinoma of pancreas

0.00

0.21

0.0

1.2

—

Other assisted single delivery

0.00

0.21

0.0

1.5

—

Cytomegaloviral disease

0.00

0.21

0.0

1.7

—

Cytomegaloviral disease, including avohilmo

0.00

0.21

0.0

1.7

—

Chronic Coagulation defects

0.00

0.21

0.0

1.5

—

Disorders of lacrimal system and orbit in diseases classified elsewhere

0.00

0.21

0.0

1.4

—

Torsion of ovary, ovarian pedicle and fallopian tube

0.00

0.21

0.0

1.0

—

Congenital iodine-deficiency syndrome/hypothyroidism

0.00

0.21

0.0

1.5

—

Serous carcinoma of ovary, including Hilmo

0.00

0.21

0.0

1.0

—

Reimbursement for rheumatic diseases

302

0.89

0.21

1.1

1.4

—

0.88

mmol/l

—

Bruxism

0.00

0.21

0.0

1.5

—

Hyperaldosteronism

0.00

0.21

0.0

1.2

—

Multiple myeloma, including Hilmo

0.00

0.21

0.0

1.2

—

Idiopathic urticaria

0.00

0.20

0.0

1.4

—

Erosion and ectropion of cervix uteri

0.00

0.20

0.0

1.0

—

Nontoxic diffuse goitre

0.00

0.20

0.0

1.4

—

Subacute thyroiditis

0.00

0.20

0.0

1.4

—

Malignant neoplasm of respiratory system and intrathoracic organs

1.22

0.16

1.3

1.2

—

mmol/l

—

L04AX Other immunosuppressants

326

0.92

0.14

1.0

1.4

—

0.93

mmol/l

—

Pain and other conditions associated with female genital organs and menstrual cycle

0.84

0.14

2.5

1.1

—

Coxarthrosis [arthrosis of hip](FG)

212

1.07

0.10

1.2

—

1.24

mmol/l

—

ILD medications: immunosuppressive drugs

382

0.95

0.09

1.1

1.2

—

0.92

mmol/l

—

Postpartum care and examination

1.05

0.08

1.3

1.5

—

Gonarthrosis [arthrosis of knee](FG)

268

1.03

0.04

1.2

—

1.17

mmol/l

—

Finngen Rheumatological endpoints

377

1.02

0.04

1.2

1.4

—

1.01

mmol/l

—

Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classified

326

0.98

0.02

2.9

1.2

—

1.18

mmol/l

—

Dysplasia of cervi uteri

1.06

0.00

1.7

1.1

—

Disorders of sclera, cornea, iris and ciliary body

324

0.99

0.00

1.5

1.4

—

0.96

mmol/l

—

Second line medication for Crohn's disease

337

1.01

0.00

1.0

1.4

—

0.96

mmol/l

—

Postmenopausal bleeding

0.95

0.00

1.0

1.1

—

mmol/l

—

Other melanin hyperpigmentation

0.00

0.0

1.0

—

Non-small cell lung cancer, including Hilmo

0.92

0.00

1.4

1.1

—

mmol/l

—

Malignant neoplasm of other connective and soft tissue

0.00

0.0

1.3

—

Malignant neoplasm of bone and articular cartilage

0.00

0.0

1.6

—

Malignant neoplasm of other and unspecified female genital organs, including Hilmo

0.00

0.0

1.0

—

Arthropathy in ulcerative colitis

0.00

0.0

1.3

—

Malignant neoplasm of other and unspecified female genital organs

0.00

0.0

1.0

—

Granuloma annulare

0.00

0.0

1.0

—

Other benign neoplasm of uterus: Other parts/unspecified

0.00

0.0

1.0

—

Crushing injury of wrist and hand

0.00

0.0

1.5

—

Non-small cell lung cancer, squamous

0.00

0.0

1.2

—

Abnormal findings on diagnostic imaging of breast

0.00

0.0

1.0

—

Use of cabergoline

0.00

0.0

1.0

—

Use of rasagiline

0.00

0.0

1.3

—

Other retinal artery occlusion

0.00

0.0

1.3

—

Urethritis and urethral syndrome

0.00

0.0

1.0

—

Vertigo of central origin

0.00

-0.00

0.0

1.2

—

0.00

-0.00

0.0

1.7

—

Family history of other conditions

0.00

-0.00

0.0

1.0

—

Melanocytic naevi of scalp and neck

0.00

-0.00

0.0

2.0

—

CR(E)ST syndrome

0.00

-0.00

0.0

1.8

—

Disorders of globe

0.00

-0.00

0.0

1.3

—

Non-Hodgkin lymphoma, all

0.00

-0.00

0.0

1.2

—

Corneal degeneration

0.00

-0.00

0.0

1.3

—

Drug-induced osteoporosis

0.00

-0.00

0.0

1.8

—

Graves ophthalmopathy, strict

0.00

-0.00

0.0

1.6

—

Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS)

0.00

-0.00

0.0

1.3

—

Liveborn infants according to place of birth

0.00

-0.00

0.0

1.0

—

Other abnormal immunological findings in serum

0.00

-0.00

0.0

1.3

—

Dementia due to Parkinson's disease

0.00

-0.00

0.0

1.4

—

Eosinophilic disease (BM)

0.00

-0.00

0.0

1.7

—

Marginal zone B-cell lymphoma, including Hilmo

0.00

-0.00

0.0

1.4

—

Infliximab

0.00

-0.00

0.0

1.1

—

Thyroiditis, unspecified

0.00

-0.00

0.0

2.0

—

Convergence insufficiency and excess

0.00

-0.00

0.0

1.3

—

Mixed connective tissue disease

0.00

-0.00

0.0

1.2

—

Benign neoplasm: Lip

0.00

-0.00

0.0

1.7

—

Endometriosis of fallopian tube

0.00

-0.00

0.0

1.0

—

Other acute disseminated demyelination

0.00

-0.00

0.0

1.2

—

Secondary malignant neoplasm of respiratory and digestive organs

0.00

-0.00

0.0

1.4

—

Endometriosis of intestine

0.00

-0.00

0.0

1.0

—

Endometriosis of ovary

1.00

-0.00

1.1

—

mmol/l

—

Abscess of external ear

0.00

-0.00

0.0

1.0

—

Hydatidiform mole

0.00

-0.00

0.0

2.0

—

Placental disorders

0.00

-0.00

0.0

1.2

—

Hereditary retinal dystrophy

0.00

-0.00

0.0

1.1

—

Other abortion

0.00

-0.00

0.0

2.2

—

Prolapse and hernia of ovary and fallopian tube

0.00

-0.00

0.0

1.0

—

Use of teriflunomide

0.00

-0.00

0.0

1.2

—

Fistulae involving female genital tract

0.00

-0.00

0.0

1.0

—

Use of fingolimod

0.00

-0.00

0.0

1.2

—

Iliotibial band syndrome

0.00

-0.00

0.0

1.7

—

Calcaneal spur

0.00

-0.00

0.0

2.0

—

Carcinoma in situ of cervix uteri, endocervix

0.00

-0.00

0.0

1.7

—

Benign neoplasm: Vagina

0.00

-0.00

0.0

2.0

—

Carcinoma in situ of skin of upper limb, including shoulder

0.00

-0.00

0.0

1.4

—

Multiple myeloma

0.00

-0.00

0.0

1.3

—

Parapsoriasis

0.00

-0.00

0.0

1.0

—

Migraine without aura, drug-induced

0.00

-0.00

0.0

1.2

—

Other specified congenital malformation syndromes affecting multiple systems

0.00

-0.00

0.0

1.3

—

Xerosis cutis

0.00

-0.00

0.0

1.0

—

Other protozoal intestinal diseases, including avohilmo

0.00

-0.00

0.0

1.6

—

Von Willebrand disease

0.00

-0.00

0.0

1.2

—

Carcinoma in situ of breast, other/unspecified

0.00

-0.00

0.0

1.0

—

Viral infections of central nervous system, not elsewhere classified/unspecifie, including avohilmod

0.00

-0.00

0.0

2.0

—

Tularaemia, including avohilmo

0.00

-0.00

0.0

1.4

—

Androgenic alopecia

0.00

-0.00

0.0

1.2

—

Malignant neoplasm of bronchus and lung, including Hilmo

0.94

-0.00

1.4

1.2

—

mmol/l

—

Brain glioblastoma

0.00

-0.00

0.0

1.3

—

Allergic contact dermatitis due to drugs in contact with skin

0.00

-0.00

0.0

1.1

—

Nasal polyp

0.92

-0.00

1.0

1.2

—

mmol/l

—

Venous complications and haemorrhoids in the puerperium

0.00

-0.00

0.0

1.0

—

Other mycoses, not elsewhere classified/unspecified, including avohilmo

0.00

-0.00

0.0

1.2

—

Third [oculomotor] nerve palsy

0.00

-0.00

0.0

1.6

—

Other lesions of median nerve

0.00

-0.00

0.0

1.6

—

Malignant neoplasm of other and unspecified parts of biliary tract, including Hilmo

0.00

-0.00

0.0

1.4

—

Viral infections of central nervous system, not elsewhere classified/unspecified

0.00

-0.00

0.0

2.0

—

Female infertility, uterine origin

0.00

-0.00

0.0

1.0

—

Other abnormal auditory perceptions

0.00

-0.00

0.0

2.2

—

Adenocarcinoma of pancreas

0.00

-0.00

0.0

1.3

—

Diseases of spleen

0.00

-0.00

0.0

1.0

—

Problems related to social environment

0.00

-0.00

0.0

1.7

—

Family history of other specific disorders

0.00

-0.00

0.0

1.0

—

Other immunodeficiencies

0.00

-0.00

0.0

1.3

—

Other and unspecified acne

0.00

-0.00

0.0

1.0

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Methanol [Moles/volume] in Serum or Plasma

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS